Trials / Terminated
TerminatedNCT05284019
Real World Effectiveness of Eptinezumab in Participants With Migraine
An Exploratory, Prospective, Randomized, Pragmatic Open Label Cohort Study to Evaluate the Comparative Effectiveness of Eptinezumab in the United States
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eptinezumab | Concentrate for solution for IV infusion |
| DRUG | Erenumab | Solution for SC Injection |
| DRUG | Onabotulinumtoxin-A | Solution for IM Injection |
| DRUG | Fremanezumab | Solution for SC Injection |
| DRUG | Galcanezumab | Solution for SC Injection |
Timeline
- Start date
- 2022-03-04
- Primary completion
- 2023-02-17
- Completion
- 2023-04-14
- First posted
- 2022-03-17
- Last updated
- 2024-05-29
- Results posted
- 2024-05-29
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05284019. Inclusion in this directory is not an endorsement.